Abstract

Recently, new exciting developments in oncology have been made in the field of liquid biopsies. In liquid biopsy, samples of blood or other body fluids are analyzed for tumor-derived material. Tumor-derived material comprises cell-free circulating tumor DNA (cf/ctDNA), exosomes released by tumor cells, or circulating tumor cells themselves (CTC). In this review, we highlight the studies that summarize the state of the art in the field of liquid biopsy, and also represent the current challenges which should be addressed in the future to successfully implement liquid biopsy in a clinical setting.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call